| Drug General Information |
| Drug ID |
D0L9YP
|
| Former ID |
DNC009857
|
| Drug Name |
4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C20H20N2O2
|
| Canonical SMILES |
C1CNCCC12C=C(C3=CC=CC=C3O2)C4=CC=C(C=C4)C(=O)N
|
| InChI |
1S/C20H20N2O2/c21-19(23)15-7-5-14(6-8-15)17-13-20(9-11-22-12-10-20)24-18-4-2-1-3-16(17)18/h1-8,13,22H,9-12H2,(H2,21,23)
|
| InChIKey |
QQXCPIPMLCDOFK-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Cytochrome P450 2D6 |
Target Info |
Inhibitor |
[1]
|
|---|
| Potassium voltage-gated channel subfamily H member 2 |
Target Info |
Inhibitor |
[1]
|
| Mu-type opioid receptor |
Target Info |
Inhibitor |
[1]
|
| Delta-type opioid receptor |
Target Info |
Inhibitor |
[1]
|
| Kappa-type opioid receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Metabolism of xenobiotics by cytochrome P450
|
|
Drug metabolism - cytochrome P450
|
|
Serotonergic synapsehsa04080:Neuroactive ligand-receptor interaction
|
|
Estrogen signaling pathway
|
|
Morphine addictionhsa04022:cGMP-PKG signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Enkephalin releaseP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Enkephalin release
|
|
Opioid proenkephalin pathway
|
|
Opioid proopiomelanocortin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Opioid prodynorphin pathway
|
|
Pathway Interaction Database
|
IL4-mediated signaling events
|
|
PathWhiz Pathway
|
Muscle/Heart Contraction
|
|
Reactome
|
XenobioticsR-HSA-1296072:Voltage gated Potassium channelsR-HSA-375276:Peptide ligand-binding receptors
|
|
G alpha (i) signalling eventsR-HSA-375276:Peptide ligand-binding receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Metapathway biotransformation
|
|
Tamoxifen metabolism
|
|
Oxidation by Cytochrome P450
|
|
Vitamin D Receptor Pathway
|
|
Aripiprazole Metabolic Pathway
|
|
Fatty Acid Omega Oxidation
|
|
Codeine and Morphine MetabolismWP706:SIDS Susceptibility Pathways
|
|
Hematopoietic Stem Cell Differentiation
|
|
Potassium ChannelsWP69:TCR Signaling Pathway
|
|
GPCRs, Class A Rhodopsin-like
|
|
Peptide GPCRs
|
|
Opioid Signalling
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like
|
|
GPCR downstream signaling
|
| References |
| REF 1 | J Med Chem. 2009 Sep 24;52(18):5685-702.Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747). |
|---|
